4:15 PM ET
8-K
Investor Presentation
Aeon Biopharma Investor Presentation
AEON Biopharma made available a new corporate presentation on its website and filed it as an exhibit to its 8-K. The presentation outlines the company's strategy to disrupt the $3.5 billion neurotoxin market with its lead candidate, ABP-450, and provides updates on its regulatory pathway and clinical milestones.